BioSante: An Unknown Company With Tremendous Potential (SeekingAlpha via Yahoo! Finance)
Shlomo Greenberg submits: Last November, drug development company BioSante Pharmaceuticals Inc. sunk to a low of $1.50, after falling from a high of $4.40 eight months earlier in March.

Ortho Biotech Revises Prescribing Information for PROCRIT(R) (Epoetin alfa) (PR Newswire via Yahoo! Finance)
Ortho Biotech Products, L.P. today revised the label for PROCRIT , acting upon guidance from the U.S. Food and Drug Administration to revise labeling for all drugs within the erythropoiesis-stimulating agent class.

Novartis Gets OK for Blood Pressure drug (First Coast News)
BASEL, Switzerland (AP) -- Swiss pharmaceutical maker Novartis AG said Tuesday it has received U.S. approval for the hypertension drug Tekturna - a potential blockbuster that has shown the ability to lower blood pressure more effectively than common treatments.